Falling Walls Falling Walls Science Summit 2023

Falling Walls Circle Plenary Table

How Generative AI Can Revolutionize Therapy Development

Johan Trygg, David Ruau, Mads Nørregaard-Madsen, Allison-Mercedes Duettmann, Mariette DiChristina, Monika Lessl

2023 Circle Plenary Tables

How Generative AI Can Revolutionize Therapy Development – Falling Walls Circle Plenary Table 2023

The rapid development of Generative Artificial Intelligence is facilitating groundbreaking applications across various industries. This Plenary Table will explore the transformative potential of Generative AI in advancing innovative therapies and realizing their great promises. The panelists will discuss the current breakthroughs and future trajectory as well as ethical considerations and challenges associated with AI-driven therapy development.

Supported by Sartorius.

Johan Trygg

Sartorius

Prof. Dr. Johan Trygg is Head of Advanced Data Analytics, Corporate Research in Sartorius where he leads the global teams on predictive modeling, AI and biology simulations to simplify and accelerate therapeutic development to unlock the potential of digitalization across biologics discovery, development and manufacturing. He is also full professor of chemometrics at Umeå University, Sweden and visiting professor in Systems Medicine at Imperial College London, UK.

David Ruau

NVIDIA

David Ruau is an experienced executive in the life science industry. David is leading strategic scientific partnership in Healthcare & Life Science across EMEA at NVIDIA. Prior to that David held different positions as CSO at a healthcare AI company, VP of Global Data Assets & Decision Science at Bayer and Head of Scientific Computing at AstraZeneca. David academic background is in computational biology of stem cell reprogramming and analytic of EHR in different therapeutic areas. David authored 30+ peer-reviewed publications and book chapters in journals like Nature, Cell, Stem Cells…

Mads Nørregaard-Madsen

Amgen

25+ years of experience in biotech and pharma. Co-founder of Nuevolution, bringing DNA-Encoded Library (DEL) technology from concept to world leading small molecule drug discovery platform. Wide experience in technology innovation, target discovery, data science and research informatics. Currently drives the integration of ML, AI and DEL technologies for small molecule research at Amgen.

Allison-Mercedes Duettmann

Foresight Institute

As president and CEO of Foresight Institute, Allison directs the AI, nano, bio, neuro, space seminars, fellowships, prizes, and tech trees. She co-edited Superintelligence: Coordination & Strategy, and co-authored Gaming the Future. She founded Foresight’s AI safety grant program, Existentialhope.com, and co-initiated The Longevity Prize. She advises organizations and projects, such as Cosmica, and The Roots of Progress Fellowship, and is on the Executive Committee of the Biomarker Consortium. She holds an MS in Philosophy & Policy from the London School of Economics, focusing on AI Safety.

Mariette DiChristina

Boston University

Mariette DiChristina, Jury Chair 2021-2022, Future Learning

Mariette DiChristina is Dean and Professor of the Practice in Journalism at the College of Communication (COM) at Boston University, her alma mater (’86). Formerly, she was Executive Vice President, Magazines, at Springer Nature, leading the award-winning global teams at the journal Nature’s magazine, Nature Research’s Community & Partnership Editorial and Publishing groups, and Scientific American, for which she served as editor in chief for 10 years.
She is a member of the National Academies of Science, Engineering, and Medicines Climate Crossroads advisory group and on the Society for Science board. She is a Fellow of the American Association for the Advancement of Science and past president of the National Association of Science Writers in the U.S. as well as Science Writers in New York.

Monika Lessl

Bayer Foundation

Monika Lessl is the Executive Director of the Bayer Foundation and Senior VP at Bayer AG, responsible for Corporate R&D and Social Innovation, as well as global societal engagement. She has been an initiator of Bayer`s Bioethics council and her passion is to drive innovation and societal transformation for a sustainable future. She is a Non-Executive Board member of Marienhaus GmbH and Futurium, and is engaged with several boards such as the Board of Trustees of the GIZ and the VCI. Monika holds a PhD in Biochemistry and a Diploma in General Management from Ashridge Business School, London. She has been ranked as “Top100 women in Innovation” by Handelsblatt in 2021.

Subscribe to our Newsletter and never miss a Breakthrough

Further Activities to have a look at